Shandong Pharmaceutical Glass Co., Ltd announced a private placement of not more than 178,490,324 class A shares for gross proceeds of not more than CNY 1,866,494,700 on September 7, 2021. The transaction will include participation from no more than 35 specific subscribers including securities investment fund management companies, securities companies, trust investment companies, financial companies, insurance institutional investors, and qualified foreign institutional investors, other qualified domestic legal person investors and natural persons. The issue price shall be not be lower than 80% of the average price of the companys stock trading on the 20 trading days prior to the pricing base date. The shares to be issued shall have a hold period of 6 months from the closing of the transaction. The transaction has been approved at the ninth session of the ninth board of supervisors and 14th meeting of the 9th board of directors of the company. The transaction still needs to be approved by the shareholders of the company, competent state-owned assets supervision and management department or its authorized body, Zibo State-owned Assets Supervision and Administration Commission, and China Securities Regulatory Commission. The validity period of resolution is 12 months from the date of review and approval by the shareholders of the company.